585 terminated. 585 Phase 1, 202 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 585 | Terminated 585 |
| Phase 2 | 202 | Terminated 202 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 4SCAR-CD44v6 T Cell Therapy Targeting Cancer CD44v6-specific CAR gene-engineered T cells - Cancers Which Are CD44v6 Positive | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-08-24 |
| NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL Antigen-specific T cells CART/CTL and DCvac - B-Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2026-06-01 | 2026-08-24 |
| NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL Antigen-specific T cells CAR-T/CTL and DCvac - T-Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2026-06-01 | 2026-08-24 |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-08-01 | 2026-10-30 |
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Pfizer | 6 | 2025-05-08 | 2026-05-08 |
| Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma CD38-SADA:177Lu-DOTA Complex - Non-hodgkin Lymphoma | Phase 1 | Terminated | Y-mAbs Therapeutics | 1 | 2025-04-21 | 2026-03-12 |
| A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) AUR104 - Select Relapsed/Refractory Lymphoid Malignancies | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 9 | 2024-12-12 | 2026-04-17 |
| A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma ONO-7018 - Non Hodgkin Lymphoma | Phase 1 | Terminated | Ono Pharmaceutical Co., Ltd. | 2 | 2024-11-27 | 2026-07-29 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ATA3219 - Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Atara Biotherapeutics | 1 | 2024-09-06 | 2026-03-11 |
| A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas ASP2802, MA-20 - B-cell Lymphoma | Phase 1 | Terminated | Astellas Pharma Global Development, Inc. | 1 | 2024-09-06 | 2025-10-28 |
| Study of Tazemetostat in Lymphoid Malignancies Tazemetostat - T-cell Lymphoma | Phase 1 | Terminated | University of Alabama at Birmingham | 6 | 2024-09-05 | 2026-04-17 |
| A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers PF-08046044/SGN-35C - Hodgkin Disease, Lymphoma, T-Cell, Peripheral | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 58 | 2024-05-28 | 2026-07-06 |
| Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma LUCAR-G39P cells product - Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | The First Affiliated Hospital with Nanjing Medical University | 11 | 2024-04-11 | 2025-12-01 |
| Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma IPH6501 - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Innate Pharma | 23 | 2024-03-04 | 2026-04-14 |
| A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers PF-08046045 - Lymphoma, T-Cell, Cutaneous, Hodgkin Disease | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 22 | 2024-02-29 | 2026-07-06 |
| C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma C752 - Lymphoma, B-Cell, CAR-T | Phase 1 | Terminated | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 2 | 2023-12-24 | 2025-02-18 |
| TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) 400mg of TQB3909 tablets, 600mg of TQB3909 tablets - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 19 | 2023-10-05 | 2025-12-30 |
| A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma GEN3017 - Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Genmab | 9 | 2023-09-21 | 2025-09-25 |
| A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. maplirpacept (PF-07901801), Glofitamab, Obinutuzumab - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 40 | 2023-08-30 | 2026-05-06 |
Showing 20 of 585. Sign in to see all of them.
Lymphoma, Non-Hodgkin (178) · Lymphoma (175) · Leukemia, Lymphocytic, Chronic, B-Cell (153) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (132) · Lymphoma, Large B-Cell, Diffuse (117) · Lymphoma, Follicular (96) · Leukemia (84) · Lymphoma, Mantle-Cell (82) · Leukemia, Myeloid, Acute (79) · Recurrence (76) · Hodgkin Disease (65) · Burkitt Lymphoma (63) · Multiple Myeloma (58) · Lymphoma, B-Cell, Marginal Zone (56) · Myelodysplastic Syndromes (55)
Hemic and Lymphatic Diseases (585) · Neoplasms by Histologic Type (568) · Immune System Diseases (566) · Immunoproliferative Disorders (563) · Lymphoproliferative Disorders (557) · Neoplasms (530) · Hematologic Diseases (310) · Lymphoma (255) · Pathological Conditions, Signs and Symptoms (251) · Pathologic Processes (248) · Leukemia, Lymphoid (246) · Disease Attributes (234) · Leukemia (197) · Chronic Disease (182)
Rituximab (74) · Cyclophosphamide (37) · Lenalidomide (23) · fludarabine (22) · venetoclax (22) · Gemcitabine (20) · Vincristine (19) · Dexamethasone (18) · Cytarabine (17) · pembrolizumab (15) · Methotrexate (14) · fludarabine phosphate (14) · ibrutinib (14) · obinutuzumab (14) · Bortezomib (13)
National Cancer Institute (NCI) (42) · M.D. Anderson Cancer Center (30) · Novartis Pharmaceuticals (13) · Gilead Sciences (12) · Masonic Cancer Center, University of Minnesota (10) · Celgene (9) · Northwestern University (9) · Pfizer (9) · Fred Hutchinson Cancer Center (8) · Merck Sharp & Dohme LLC (8) · Hoffmann-La Roche (7) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (7) · Incyte Corporation (6) · Therapeutic Advances in Childhood Leukemia Consortium (6) · Washington University School of Medicine (6)
United States (479) · Spain (56) · France (53) · Italy (45) · China (39) · Australia (35) · United Kingdom (33) · Canada (30) · Germany (30) · South Korea (22) · Japan (18) · Netherlands (16) · Belgium (15) · Poland (13) · Israel (10)
Ajay Gopal (4) · David S Schrump, M.D. (3) · Roger Strair, MD, PhD (3)
PMID 34515338, PMID 34398557, PMID 31527168, PMID 32823563, PMID 35226739, PMID 35622074, PMID 36597128, PMID 39097413, PMID 18645136, PMID 19029442, PMID 19139736, PMID 19238148, PMID 20460644, PMID 20563869, PMID 21289631, PMID 21502553, PMID 22080439, PMID 22080968, PMID 22239668, PMID 22250189, PMID 22448921, PMID 23092873, PMID 23233571, PMID 23256542, PMID 23393050, PMID 24241210, PMID 24276047, PMID 24355079, PMID 24615776, PMID 24615777, PMID 24615778, PMID 25189481, PMID 25441108, PMID 26139427, PMID 26472751, PMID 26567113, PMID 26687959, PMID 27118540, PMID 28903943, PMID 29141948, PMID 29296805, PMID 29322091, PMID 29432154, PMID 29477379, PMID 29610115, PMID 29735994, PMID 30444200, PMID 30711772, PMID 30867794, PMID 30962222
2018 (11), 2015 (8), 2023 (8), 2016 (7), 2014 (6), 2017 (6), P30CA015704 (6), U01CA076576 (6), 2019 (5), P30CA015083 (4), U01CA097452 (4), P01CA044991 (3), P30CA006973 (3), P30CA016058 (3), P30CA043703 (3)